<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8106540</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6583</journal-id>
<journal-id journal-id-type="nlm-ta">Prenat Diagn</journal-id>
<journal-id journal-id-type="iso-abbrev">Prenat. Diagn.</journal-id>
<journal-title-group>
<journal-title>Prenatal diagnosis</journal-title>
</journal-title-group>
<issn pub-type="ppub">0197-3851</issn>
<issn pub-type="epub">1097-0223</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27718271</article-id>
<article-id pub-id-type="pmc">5243851</article-id>
<article-id pub-id-type="doi">10.1002/pd.4935</article-id>
<article-id pub-id-type="manuscript">NIHMS828905</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bassett</surname>
<given-names>Anne S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Costain</surname>
<given-names>Gregory</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marshall</surname>
<given-names>Christian R.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>The Dalglish Family 22q Clinic, Department of Psychiatry, University Health Network, Toronto, Ontario, Canada</aff>
<aff id="A2"><label>2</label>Department of Psychiatry, and Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</aff>
<aff id="A3"><label>3</label>Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff>
<aff id="A4"><label>4</label>Medical Genetics Residency Training Program, University of Toronto, Toronto, Ontario, Canada</aff>
<aff id="A5"><label>5</label>The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada</aff>
<aff id="A6"><label>6</label>Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada</aff>
<author-notes>
<corresp id="CR1"><bold>Corresponding author:</bold> Anne S. Bassett, The Dalglish Family 22q Clinic, Toronto General Hospital, 200 Elizabeth Street, 8NU, Room 802, Toronto, Ontario, Canada, M5G 2C4, Phone: (416) 340-5145, Fax: (416) 340-5004, <email>anne.bassett@utoronto.ca</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>37</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>69</lpage>
<!--elocation-id from pubmed: 10.1002/pd.4935-->
<abstract>
<p id="P1">Most major neuropsychiatric outcomes of concern to families are not detectable by prenatal ultrasound. The introduction of genome-wide chromosomal microarray analysis to prenatal clinical diagnostic testing has increased the detection of pathogenic 22q11.2 deletions, which cause the most common genomic disorder. The recent addition of this and other microdeletions to non-invasive prenatal screening methods using cell-free fetal DNA has further propelled interest in outcomes. Conditions associated with 22q11.2 deletions include intellect ranging from intellectual disability to average, schizophrenia and other treatable psychiatric conditions, epilepsy, and early-onset Parkinsonâ€™s disease. However, there is currently no way to predict how severe the lifetime expression will be. Available evidence suggests no major role in these neuropsychiatric outcomes for the congenital cardiac or most other structural anomalies that may be detectable on ultrasound. This article provides an outline of the lifetime neuropsychiatric phenotype of 22q11.2 deletion syndrome that will be useful to clinicians involved in prenatal diagnosis and related genetic counselling. The focus is on information that will be most relevant to two common situations: detection of a 22q11.2 deletion in a fetus or newborn, and new diagnosis of 22q11.2 deletion syndrome in a parent without a previous molecular diagnosis.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>